An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines

Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S (Vaxzevria, AstraZeneca). Methods: 197 healthcare...

Descripción completa

Detalles Bibliográficos
Autores principales: Vallée, Alexandre, Vasse, Marc, Mazaux, Laurence, Bonan, Brigitte, Amiel, Carline, Zia-Chahabi, Sara, Chan-Hew-Wai, Aurélie, Farfour, Eric, Camps, Eve, Touche, Pauline, Barret, Flavie, Parquin, François, Zucman, David, Fourn, Erwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/
https://www.ncbi.nlm.nih.gov/pubmed/34501264
http://dx.doi.org/10.3390/jcm10173817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432244/
https://www.ncbi.nlm.nih.gov/pubmed/34501264
http://dx.doi.org/10.3390/jcm10173817

Ejemplares similares